# Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection

> **NCT05867056** · PHASE1 · WITHDRAWN · sponsor: **Immunocore Ltd**

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** IMC-I109V Single Ascending Dose
- **DRUG:** IMC-I109V Multiple Ascending Doses
- **DRUG:** HBV HCC Module MAD

## Key facts

- **NCT ID:** NCT05867056
- **Lead sponsor:** Immunocore Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-08-12
- **Primary completion:** 2024-09-10
- **Final completion:** 2024-12-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Enrollment into the phase 2 portion was never initiated.
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05867056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05867056, "Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05867056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*